GASTROESOPHAGEAL-JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL-JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL-JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL-JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in stomach cancer fight
Disease control CompletedThis study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug or a placebo before and after surgery. The goal was to see if the combination improves outcomes l…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
Immunotherapy combo shows promise in stomach cancer trial
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. Over 1,000 adults received either the drug combo or chemo alone before and after surgery. The goal was to see if the combi…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Real-World data on nivolumab for stomach cancer: what happened?
Knowledge-focused CompletedThis study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer. All patients received nivolumab as their first treatment. The goal was to see how well the drug worked in real life and how it was used. This was an observa…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 19, 2026 11:47 UTC